Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
China
· Delayed Price · Currency is CNY 20.97
-0.12 (-0.57%)
Apr 30, 2026, 1:05 PM CST
SHA:605177 Revenue
In the year 2025, Zhejiang East Asia Pharmaceutical had annual revenue of 940.19M CNY, down -21.54%. Zhejiang East Asia Pharmaceutical had revenue of 343.85M in the quarter ending December 31, 2025, with 46.18% growth.
Revenue
940.19M
Revenue Growth
-21.54%
P/S Ratio
2.52
Revenue / Employee
537.56K
Employees
1,749
Market Cap
2.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 940.19M | -258.05M | -21.54% |
| Dec 31, 2024 | 1.20B | -158.21M | -11.66% |
| Dec 31, 2023 | 1.36B | 176.89M | 15.00% |
| Dec 31, 2022 | 1.18B | 467.34M | 65.62% |
| Dec 31, 2021 | 712.22M | -169.45M | -19.22% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guiyang Xintian Pharmaceutical | 749.72M |
| Shanghai Hile Bio-Technology | 246.35M |
| Jiangsu CoWin Biotech | 193.52M |
| Shanghai Universal Biotech | 1.07B |
| Suzhou Fushilai Pharmaceutical | 412.51M |
| Jiangsu Gdk Biological Technology | 110.32M |
| Cabio Biotech (Wuhan) | 418.18M |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |